Real-life glycaemic profiles in non-diabetic individuals with low fasting glucose and normal HbA1c: the A1C-Derived Average Glucose (ADAG) study by Borg, R. et al.
SHORT COMMUNICATION
Real-life glycaemic profiles in non-diabetic individuals
with low fasting glucose and normal HbA1c: the A1C-Derived
Average Glucose (ADAG) study
R. Borg & J. C. Kuenen & B. Carstensen & H. Zheng & D. M. Nathan & R. J. Heine &
J. Nerup & K. Borch-Johnsen & D. R. Witte & on behalf of the ADAG Study Group
Received: 16 February 2010 /Accepted: 9 March 2010 /Published online: 16 April 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Real-life glycaemic profiles of healthy
individuals are poorly studied. Our aim was to analyse to
what extent individuals without diabetes exceed OGTT
thresholds for impaired glucose tolerance (IGT) and diabetes.
Methods In the A1C-Derived Average Glucose (ADAG)
study, 80 participants without diabetes completed an
intensive glucose monitoring period of 12 weeks. From
these data, we calculated the average 24 h glucose exposure
as time spent above different plasma glucose thresholds.
We also derived indices of postprandial glucose levels,
glucose variability and HbA1c.
Results We found that 93% of participants reached glucose
concentrations above the IGT threshold of 7.8 mmol/l and
spent a median of 26 min/day above this level during
continuous glucose monitoring. Eight individuals (10%)
spent more than 2 h in the IGT range. They had higher
HbA1c, fasting plasma glucose (FPG), age and BMI than
those who did not. Seven participants (9%) reached glucose
concentrations above 11.1 mmol/l during monitoring.
Conclusions/interpretation Even though the non-diabetic
individuals monitored in the ADAG study were selected on
the basis of a very low level of baseline FPG, 10% of these
spent a considerable amount of time at glucose levels
considered to be ‘prediabetic’ or indicating IGT. This
highlights the fact that exposure to moderately elevated
glucose levels remains under-appreciated when individuals
are classified on the basis of isolated glucose measurements.
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Abbreviations
ADAG A1C-Derived Average Glucose
CGM Continuous interstitial glucose monitoring
FPG Fasting plasma glucose
IGT Impaired glucose tolerance
IQR Interquartile range
Introduction
Current understanding of normoglycaemia is largely based
on studies of populations without diabetes, often with a
small number of glucose measurements per individual. This
results in limited insight into patterns of real-life glycaemia
as experienced by healthy individuals. As new options in
diabetes treatment increasingly focus on specific glucose
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have a clearer understanding of what constitutes a normal
glucose profile. Knowledge of how much time normogly-
caemic individuals spend at different levels of glycaemia
under real-life conditions is needed to serve as a benchmark
for the more detailed study of impaired glycaemic states and
the ability of novel treatments to normalise glucose profiles.
We therefore studied the glucose profiles of non-diabetic
individuals who participated in the A1C-Derived Average
Glucose (ADAG) study. This observational study included
continuous interstitial glucose monitoring (CGM) under
real-life conditions. Our aim was to analyse to what extent
individuals without diabetes exceed OGTT thresholds for
impaired glucose tolerance (IGT) and diabetes [1].
Methods
Study participants The ADAG study was conducted at ten
centres in the USA, Europe and Africa from 2006 to 2008.
The aim was to define the relationship between HbA1c and
average glucose levels. A full description of the study has
been published [2]. The population for the present analysis
consisted of the 80 non-diabetic control participants who
completed the intensive glucose monitoring period of
12 weeks. The non-diabetic participants were selected on
the basis of having no history of diabetes, a plasma glucose
level ≤5.4 mmol/l (97 mg/dl) after an overnight fast and
HbA1c <6.5%. The plasma glucose cut-off was chosen due
to its high specificity for excluding diabetes without
performing an OGTT [3].
The study was approved by the human studies commit-
tees at the participating institutions, and informed consent
was obtained from all participants.
Assessing glycaemia Glucose levels were assessed with
two different methods during the study period. CGM
(Medtronic Minimed, Northridge, CA, USA) was per-
formed for at least 48 h at baseline and three times at
4 week intervals during the 12 week study period.
Participants also measured an eight-point self-monitored
blood glucose profile (preprandial, 90 min postprandial,
pre-bedtime and 03:00 hours) using a handheld glucose
meter (Glucose 201 Plus; HemoCue, Ängelholm, Sweden)
during the days of CGM. This protocol yielded approxi-
mately 2,300 glucose values for each participant. The
median time of CGM was 230 h per participant. All glucose
concentrations presented are plasma glucose equivalents.
As an indicator of overall hyperglycaemia, the time
spent above selected glucose thresholds was calculated for
the first 24 h of each CGM monitoring period after the
initial 2 h calibration period. The mean of these time
periods was used. This was done for glucose concentrations
corresponding to the different cut-off points in the diag-
nostic criteria, i.e. 6.1, 7.0, 7.8, 11.1 and 16.7 mmol/l (110,
126, 140, 200 and 300 mg/dl, respectively).
Pre- and postprandial measurements for self-monitored
blood glucose (HemoCue) were used to calculate mean pre-
and postprandial plasma glucose. Pre-breakfast plasma
glucose was defined as fasting plasma glucose (FPG).
HbA1c samples were analysed with four highly intercorre-
lated, DCCT-aligned assays, all of which have been
approved by the National Glycohemoglobin Standardiza-
tion Program (www.ngsp.org/, accessed 1 February 2010).
The mean value at the end of the 12 week study period was
used [2].
Results
The study population had a mean age of 41 years (SD
13.8); 69% were women and 68% white, with mean HbA1c
of 5.2% (SD 0.3), and mean BMI of 25.9 kg/m
2 (5.5) for
men and 25.0 kg/m
2 (3.3) for women.
During the monitoring period, median FPG was
5.3 mmol/l with an interquartile range (IQR) of 4.9 to
5.6 mmol/l. Median preprandial plasma glucose was
5.3 mmol/l (IQR 5.1–5.6 mmol/l) and median postprandial
plasma glucose was 6.0 mmol/l (IQR 5.7–6.3 mmol/l).
Glucose variability during CGM, measured as mean (SD),
was 0.8 mmol/l (0.2).
Table 1 shows the proportion of participants who
reached selected glucose thresholds at any time during
CGM measurement and the time these participants spent
above each threshold. Figure 1 shows distribution of the
time spent by individuals above selected glucose concen-
trations. Participants reaching at least 7.8 mmol/l spent a
median of 31 min/day (range 0–412 min) above this IGT
level. Aquarterofthetotalcohort experienced glucose levels
Table 1 Time (per 24 h CGM period) spent above selected plasma
glucose concentrations
PG, mmol/l (mg/dl) Participants
reaching PG
level
a,%( n)
Median time
above PG
level (min)
a, b
IQR
b (min)
>6.1 (110) 100 (80) 395 273–688
>7.0 (126) 99 (79) 109 45–200
>7.8 (140) 93 (74) 31 11–81
>11.1 (200) 9 (7) 8 3–62
>16.7 (300) 1 (1) 32 –
aPG level specified in column 1
bFor participants reaching specific PG level
IQR, interquartile range; PG, plasma glucose
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individuals (3.8%) remained in this range for 5 h or more per
day. These three individuals had HbA1c levels in the normal
range (5.4–5.7%) and mean FPG between 4.9 and
6.5 mmol/l. The eight individuals who spent more than
2 h above the IGT cut-off had higher mean HbA1c (5.7%),
FPG (6.1 mmol/l),age (55 years)and BMI (women 29kg/m
2,
men 30 kg/m
2) than those who did not. The proportion of
non-white participants and women (six of eight for both) was
higher than in the whole study population. Seven persons
(9%) reached 11.1 mmol/l, with two individuals spending
more than 1 h/24 h above this diabetic level.
Discussion
We found that nearly all individuals without diabetes
exceeded the IGT threshold of 7.8 mmol/l (140 mg/dl) at
some point during the day and spent a median of 26 min
(range 0 min to 6 h 52 min) per day above this level. We also
found that one in ten individuals reached diabetic levels
(11.1 mmol/l, 200 mg/dl). These findings suggest that
glucose levels in persons without diabetes frequently reach
IGT range concentrations and that a considerable proportion
reach diabetic levels. Previous smaller studies have sug-
gested similar patterns, albeit in more homogeneous popula-
tions. A study in 32 individuals with confirmed normal
glucose tolerance found thatseven participants(22%) reached
glucose concentrations above 11.1 mmol/l (200 mg/dl) during
an average of 28 days of CGM and that participants spent on
average 42 min/day at glucose concentrations above
7.8 mmol/l (140 mg/dl) [4]. In a smaller study, 15 hospital
staff without known diabetes and monitored by CGM for
24 h were found to spend an average of 72 min/day with
glucose levels higher than 7.0 mmol/l (126 mg/dl) [5].
During a standardised OGTT, it is well established that
glucose concentrations can exceed 7.8 mmol/l in individ-
uals with normal glucose tolerance in the time preceding
the 2 h value [6]. However, since the 75 g OGTT is an
extreme glucose load compared with an average mixed
meal with regard to glucose concentration and the simple
carbohydrate content (fast uptake), our results, which were
based on real-life monitoring over a prolonged period, add
an important dimension.
The limitations of the current study include the absence
of OGTTs to rule out diabetes with certainty or to classify
participants as having IGT. Our fasting plasma glucose
exclusion criterion has been shown to be highly specific for
ruling out diabetes [3], but does not rule out the possibility
that some of the participants could have had IGT. In
addition, our HbA1c exclusion criterion of ≥6.5% has
recently been proposed as the new diagnostic level for
diabetes [7]. At 5.2% (SD 0.3), mean HbA1c in the present
population was considerably lower. Factors that cause
glucose fluctuations, such as food intake, exercise, stress,
or beta cell function and insulin sensitivity, were not
examined in this study under free-living conditions.
However, the present observations are relevant in public
health terms, and to clinicians dealing with individuals with
a wide, often unknown array of dietary and physical
activity patterns.
Our results confirm that considerable variability of
glucose levels exists even among individuals classified as
not having diabetes. These findings may lead to specula-
tion on the adequacy of current diagnostic practice and
whether the use of multiple glucose measurements at
different time points of the day or assessment of HbA1c
would identify hyperglycaemic individuals more accurately.
However, in the absence of data assessing the impact of
these glucose profiles on clinical endpoints, the current
study cannot establish whether periods of transient hyper-
glycaemia are part of normal variability or whether such
periods affect the risk of progression to diabetes and
development of diabetic complications.
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Fig. 1 Proportion of individuals
spending time with plasma
glucose concentrations above
selected glucose thresholds
(per 24 h monitoring period) of
a 7.8 mmol/l, b 11.1 mmol/l
and c 16.7 mmol/l
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When glucose levels are measured under real-life condi-
tions in non-diabetic individuals, as defined by a very low
level of FPG and HbA1c levels below 6.5%, these
individuals are seen to spend a considerable amount of
time with glucose levels classified as ‘dysglycaemic’ or
even diabetic. Since chronic glucose exposure is considered
to be one of the main mediators of long-term outcomes,
including microvascular and cardiovascular disease, our
findings demonstrate that exposure to moderately elevated
glucose levels remains under-appreciated when individuals
are classified on the basis of isolated glucose measure-
ments. If no adverse outcomes attend these periods of
hyperglycaemia, our findings suggest that it is common for
persons who are regarded as ‘normoglycaemic’ by accepted
current definitions to experience transient hyperglycaemia
during everyday circumstances.
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